An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

Inclusion Criteria: * Subject must be ambulatory * Subject must have atteneded the 20010223 end-of-study visit and have completed all tests and procedures during the end-of-study visit * signed informed consent must be obtained before any study-specific procedures Exclusion Criteria: * Experienced severe and/or serious adverse event which were thought to be related to denosumab administration during the 20010223 study. * Developed grade 3 or 4 laboratory abnormalities based on Common Terminology Criteria for Adverse Events v3.0 during the 20010223 study which did not normalized upon follow up or did not have diagnosis or treatment. * Newly diagnosed conditions such as hyper/hypo thyroidism, rheumatoid arthritis, other bone diseases, renal disease. * Using therapies while participating in the 20010223 study such as oral bisphosphonates, calcitonin, oral strontium, SERMS, systemic glucocortiocosteriods.